We found that the CTL induced with the melanoma peptide MART-127-35 encapsulated into our nanoparticles were able to recognize and kill specifically not only the peptide-pulsed T2 cells, but also the HLA-A2-positive melanoma cells 624. The gene discussed is SEPTIN4; the disease is melanoma.